(PRESSEMITTEILUNG) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat eine exklusive weltweite Kooperationsvereinbarung mit IGM Biosciences, Inc. (Nasdaq: IGMS), einem Biotechnologieunternehmen im klinischen Stadium, das sich auf … Read the full press release
(PRESS RELEASE) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced an exclusive worldwide collaboration agreement signed with IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and … Read the full press release
(PRESSEMITTEILUNG) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat angekündigt, dass das Unternehmen auf seinem Immunology Investor Event, das am Dienstag, den 29. März ab 14:00 Uhr … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronisch entzündliche Erkrankungen, chronisch obstruktive Lungenerkrankung, COPD, dupilumab, Dupixent®, Immunologie, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetische Zytokine, TAILORED COVALENCY™, Typ-2-Entzündung
(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronic inflammatory diseases, Chronic obstructive pulmonary disease, COPD, dupilumab, Dupixent, immunology, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetic cytokines, Tailored Covalency®, type 2 inflammation
Europe Mental Health Software and Devices Market to Experience Great Bounce in European Markets (PRESS RELEASE) NEW YORK, 21-Mar-2022 — /EuropaWire/ — Every year, over 7 Million people are known to die by suicide, one of the major concerns of … Read the full press release
Posted in Business, Healthcare, Internet & Online, Marketing, News, Pharma & Biotech, Technology
Tagged Kenneth Research, mental health, Mental Health Devices, Mental Health Devices Market Demand, Mental Health Devices Market Drivers, Mental Health Devices Market Major Players, Mental Health Devices Market opportunity
El desafío tiene como objetivo ayudar al descubrimiento de avances transformadores en las áreas de enfermedades centrales de AstraZeneca. Las propuestas exitosas asegurarán puestos de investigación posdoctorales totalmente financiados (COMUNICADO DE PRENSA) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), … Read the full press release
The challenge aims at helping the discovery of transformative breakthroughs across AstraZeneca’s core disease areas Successful proposals will secure fully funded postdoctoral research positions (PRESS RELEASE) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology … Read the full press release
Sandoz obtiene capacidades y activos significativos en el desarrollo de dispositivos médicos y medicamentos que apuntan a importantes oportunidades de crecimiento en genéricos complejos y respiratorios Las enfermedades respiratorias son la principal causa de muerte y discapacidad e imponen una … Read the full press release
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide Acquisition … Read the full press release
Zulassungsantrag für die Behandlung von Anämie bei chronischer Nierenerkrankung basierend auf dem klinischen Phase-III-Studienprogramm ASCEND, bestehend aus fünf Studien, die alle ihre co-primären Wirksamkeits- und Sicherheitsendpunkte erreichten Die Zulassung der EMA-Anträge ist der erste große regulatorische Meilenstein für Daprodustat seit … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged American Society of Nephrology, Anämie, ASCEND-D, ASCEND-ND, Behandlung von Anämie, chronische Nierenerkrankung, CKD, daprodustat, Dialyse, EMA, Europäische Arzneimittel-Agentur, GlaxoSmithKline, Hämoglobin, HIF-PHI, klinisches Studienprogramm ASCEND Phase III, MAA, Prolylhydroxylase-Hemmer, Zulassungsantrag
Submission for the treatment of anaemia of chronic kidney disease based on the ASCEND Phase III clinical trial programme, consisting of five trials that all met their co-primary efficacy and safety endpoints EMA file acceptance is the first major regulatory … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, United Kingdom
Tagged American Society of Nephrology, anaemia, ASCEND Phase III clinical trial programme, ASCEND-D, ASCEND-ND, Chronic kidney disease, CKD, daprodustat, dialysis, EMA, European Medicines Agency, GlaxoSmithKline, haemoglobin, HIF-PHI, MAA, Marketing Authorisation Application, prolyl hydroxylase inhibitor, treatment of anaemia
(PRESS RELEASE) LOS ANGELES, CA, United States, 17-Feb-2022 — /EuropaWire/ — Elios Vision Inc. announced today 8-year follow up results of its novel ELIOS® Excimer Laser Trabeculostomy procedure combined with cataract surgery. Key study findings: 161 eyes of 128 patients … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology
Tagged cataract, cataract removal, cataract surgery, ELIOS procedure, Elios Vision Inc., ELIOS®, Excimer Laser Trabeculostomy, glaucoma, glaucoma surgeries, glaucoma surgery, IDE, investigational device exemption, IOP reduction, MIGS, Minnesota Eye Consultants, ocular hypertension, ophthalmic surgeons, Phaco-ELIOS, Thomas W. Samuelson MD, University of Minnesota
(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé l’approbation par l’Union européenne (UE) de son médicament Saphnelo (anifrolumab) en tant que traitement d’appoint pour le traitement des patients … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an European Union (EU) approval for its Saphnelo (anifrolumab) medicine as an add-on therapy for the treatment of adult patients with … Read the full press release
Dans les études YOSEMITE et RHINE sur l’œdème maculaire diabétique, au moins 60 % des patients Vabysmo éligibles pourraient prolonger le traitement à tous les quatre mois à deux ans, contre 50 % à la première année Près de 80 % des … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged affections rétiniennes, angiogenèse, anticorps bispécifique, DME, DMLA néovasculaire, exsudation et dégénérescence 2022, injections oculaires, Levi Garraway MD Ph.D., médecine oculaire, perte de vision, ranibizumab, RHIN, Roche, Susvimo, Susvimo Archway, Vabysmo, YOSEMITE, œdème maculaire diabétique
In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one Almost 80% of eligible Vabysmo patients could extend treatment to every … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged Angiogenesis, bispecific antibody, diabetic macular edema, DME, Exudation and Degeneration 2022, eye injections, eye medicine, Levi Garraway M.D. Ph.D., Neovascular AMD, ranibizumab, retinal conditions, RHINE, Roche, Susvimo, Susvimo Archway, Vabysmo, vision loss, YOSEMITE
HILDEN, Deutschland, GERMANTOWN, Maryland (USA), und SHANGHAI, China, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA), ein deutscher Anbieter von Sample-to-Insights-Lösungen, die es Kunden ermöglichen, Einblicke in die Bausteine des Lebens – DNA, RNA und Proteine … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON Tuberkulose, QuantiFERON-TB Gold Plus, TB-Bakterien, TB-Diagnose, TB-Infektionen, TB-Tests, TST, Tuberkulin-Hauttest, UNITAID, Weltgesundheitsorganisation, WHO
(COMMUNIQUÉ DE PRESSE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE : QGEN ; Frankfurt Prime Standard : QIA), une société allemande fournisseur de solutions Sample to Insights qui permettent aux clients de débloquer des informations sur … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Académie chinoise des sciences médicales, bactérie de la tuberculose, dépistage de la tuberculose, diagnostic de la tuberculose, Dr. Gao Lei, IGR, infections tuberculeuses, Jean-Pascal Viola, NMPA, OMS, Organisation mondiale de la santé, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB® Gold Plus, test cutané à la tuberculine, TST, UNITAID
(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a German provider of Sample to Insights solutions that enable customers to unlock insights from the building … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN N.V., QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB Gold Plus, TB bacteria, TB diagnosis, TB infections, TB testing, TST, Tuberculin Skin Test, UNITAID, WHO, World Health Organization
(PRESS RELEASE) MELBOURNE, Australia, 3-Feb-2022 — /EuropaWire/ — Australian technologist Dr Ian Dixon founded Exopharm in 2013 with the vision to harness the unique properties of exosomes as a new class of medicine. Dixon’s decisive early entry into exosome therapeutics … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology
Tagged AAVs, adeno-associated viral vectors, Arch Ventures, Australian technologist, Biotech, Codiak Biociences, Daisy Scarborough, DNA/RNA, Dr Ian Dixon, Evox Therapeutics, EVPS, Exopharm, Exoria, exosome therapeutics, exosomes, gene therapies, genetic disorders, LEAP™, lipid nanoparticles, LNPs, LOAD, Lonza, medicine, Pharmaceutical, vaccines
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?